Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic infl...
Saved in:
Main Authors: | Eleftheria Galatou (Author), Elena Mourelatou (Author), Sophia Hatziantoniou (Author), Ioannis S. Vizirianakis (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gene Therapy with Chitosan Nanoparticles: Modern Formulation Strategies for Enhancing Cancer Cell Transfection
by: Varvara Antoniou, et al.
Published: (2024) -
Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
by: James Twiss, et al.
Published: (2023) -
Genistein Modulated Lipid Metabolism, Hepatic PPARγ, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH)
by: Sudaporn Pummoung, et al.
Published: (2020) -
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis
by: Akifumi Kushiyama, et al.
Published: (2016) -
Oligonucleotide therapies for nonalcoholic steatohepatitis
by: Sixu Li, et al.
Published: (2024)